CD4+ T cells mediate vascular normalization in breast cancer models11, and bevacizumab-induced vascular normalization in these TNBC patients9 via Ang2 suppression could mediate the increase in CD8+ T-cell density. The gene discussed is CD8A; the disease is breast cancer.